抗幽门螺杆菌治疗对急性冠脉综合征合并幽门螺杆菌感染患者炎性标记物的影响  

Effect of Anti-Helicobacter pylori Therapy on Inflammatory Markers in Patients with Helicobacter pylori Infection in Acute Coronary Syndrome

作　　者：谢杰[1] XIE Jie(School infirmary,Fujian Normal University,Fuzhou 350007,China)

机构地区：[1]福建师范大学医院,福建福州350007

出　　处：《海峡药学》2022年第10期104-107,共4页Strait Pharmaceutical Journal

摘　　要：目的 研究抗幽门螺杆菌治疗对急性冠脉综合征幽门螺杆菌感染患者炎性标记物的影响。方法 本次研究对象为2017年12月至2020年11月期间在本院接受治疗的急性冠脉综合征合并幽门螺杆菌感染患者,按照随机数字表法将74例患者进行分组,对照组37例实施常规治疗,观察组37例加用抗幽门螺杆菌治疗。将两组的炎性标记物水平、心电图复常时间、胸痛改善时间、临床疗效、Hp根除率、不良反应发生情况、心脏不良事件发生率进行比较。结果 观察组患者治疗后的IL-6、CRP、s ICAM-1水平低于对照组,观察组的心电图复常时间、胸痛改善时间短于对照组,差异具有统计学意义(P <0.05);观察组患者的治疗总有效率(94.59%)、Hp根除率(91.89%)高于对照组,心脏不良事件发生率(13.51%)低于对照组,差异具有统计学意义(P <0.05);两组比较不良反应发生率差异无统计学意义(P> 0.05)。结论 在急性冠脉综合征合并幽门螺杆菌感染患者治疗中实施抗幽门螺杆菌治疗能够减少心脏不良事件的发生,具有较高的治疗有效性和安全性。OBJECTIVE To study the effect of anti-Helicobacter pylori therapy on inflammatory markers in patients with Helicobacter pylori( Hp) infection in acute coronary syndrome.METHODS The subjects of this study were patients with acute coronary syndrome complicated with Hp infection who were treated in our hospital from December 2017 to November 2020.According to the random number table method,74 patients were divided into two groups,37 patients in the control group were given routine treatment and 37 patients in the observation group were given anti-Hp treatment.The levels of inflammatory markers,ECG normalization time,chest pain improvement time,clinical efficacy,Hp eradication rate,adverse reactions,and cardiac adverse events were compared between the two groups.RESULTS The levels of IL-6,CRP,and s ICAM-1 in the observation group were lower than those in the control group.The ECG recovery time and chest pain improvement time in the observation group were shorter than those in the control group.The difference was statistically significant( P 0.05).CONCLUSION Anti-Hp therapy in the treatment of patients with acute coronary syndrome with Hp infection can alleviate inflammation,effectively eradicate Hp,reduce the occurrence of adverse cardiac events,and has high therapeutic effectiveness and safety.

关 键 词：急性冠脉综合征 幽门螺杆菌 感染 炎性标记物 

分 类 号：R969.4[医药卫生—药理学]